| 1 |
Tatematsu D, Akao M, Park H, Iwami S, Ejima K, Iwanami S. Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors. J Theor Biol 2023;561:111403. [PMID: 36586664 DOI: 10.1016/j.jtbi.2022.111403] [Reference Citation Analysis]
|
| 2 |
Schilling WHK, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, Luvira V, Pongwilai S, Cruz C, Callery JJ, Boyd S, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Piaraksa N, Suwannasin K, Hanboonkunupakarn P, Hanboonkunupakarn B, Sookprome S, Poovorawan K, Thaipadungpanit J, Blacksell S, Imwong M, Tarning J, Taylor WRJ, Chotivanich V, Sangketchon C, Ruksakul W, Chotivanich K, Teixeira MM, Pukrittayakamee S, Dondorp AM, Day NPJ, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). Elife 2023;12. [PMID: 36803992 DOI: 10.7554/eLife.83201] [Reference Citation Analysis]
|
| 3 |
Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, Cowling BJ, Leung GM. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis 2023:S1473-3099(22)00873-8. [PMID: 36796397 DOI: 10.1016/S1473-3099(22)00873-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 4 |
Jittamala P, Schilling WH, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, Almeida PJ, Ekkapongpisit M, Cruz C, Callery JJ, Boyd S, Anunsittichai O, Hongsuwan M, Singhaboot Y, Pagornrat W, Tuntipaiboontana R, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Keayarsa S, Madmanee W, Aguiar RS, Santos FM, Batty EM, Hanboonkunupakarn P, Hanboonkunupakarn B, Sookprome S, Poovorawan K, Imwong M, Taylor WR, Chotivanich V, Sangketchon C, Ruksakul W, Chotivanich K, Pukrittayakamee S, Dondorp AM, Day NP, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ. Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants.. [DOI: 10.1101/2022.10.17.22281161] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Kinoshita T, Shinoda M, Nishizaki Y, Shiraki K, Hirai Y, Kichikawa Y, Tsushima K, Shinkai M, Komura N, Yoshida K, Kido Y, Kakeya H, Uemura N, Kadota J. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med 2022;20:342. [PMID: 36163020 DOI: 10.1186/s12916-022-02518-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Schilling WH, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, Luvira V, Pongwilai S, Cruz C, Callery JJ, Boyd S, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Piaraksa N, Suwannasin K, Hanboonkunupakarn P, Hanboonkunupakarn B, Sookprome S, Poovorawan K, Thaipadungpanit J, Blacksell S, Imwong M, Tarning J, Taylor WR, Chotivanich V, Sangketchon C, Ruksakul W, Chotivanich K, Teixeira MM, Pukrittayakamee S, Dondorp AM, Day NP, Piyaphanee W, Phumratanaprapin W, White NJ. Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19.. [DOI: 10.1101/2022.07.15.22277570] [Reference Citation Analysis]
|
